Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2010

View Archived Issues

IMGN-388 shows preliminary anticancer activity in phase I trial

NKTR-105 advances into phase I evaluation in solid tumors

Ridaforolimus shows promise in pediatric patients with refractory solid tumors

Merck KGaA describes new HSP 90 inhibitors

AstraZeneca claims new DNA gyrase/topoisomerase 4 inhibitors

Novartis identifies new VEGFR-2 inhibitors

Novel renin inhibitors disclosed by Merck Frosst

New morphine-6-glucuronide derivatives claimed by sanofi-aventis as analgesics

Affitech begins preclinical development of human antibodies for cancer treatment

DPP-IV inhibitor LC15-0444 safe and improves glycemic control in Korean type 2 diabetes patients

New glucagon receptor antagonist DSR-17759 shows antidiabetic promise in preclinical evaluation

Pitavastatin displays better 12-month clinical outcomes vs. no statin therapy in STEMI patients

Enrollment completed in phase IIa study of MP4OX for hemorrhagic shock

Cardio3 BioSciences reports 3-month data C-Cure stem cell therapy trial

FDA accepts for review BioMimetic's PMA for Augment bone graft

Endo submits complete response to FDA regarding NDA for Fortesta

Advanced Life Sciences submits SPA to FDA for Restanza in CABP

Sirnaomics receives grants for developing its siRNA therapeutics

Celgene and Abraxis BioScience sign merger agreement

Eisai to market lorcaserin for obesity and weight management in the U.S.

Threshold initiates phase II TH-302 trial in advanced pancreatic cancer

Rifapentine obtains orphan drug status in Europe for tuberculosis

Chelsea reports interim results of phase II trial of droxidopa in fibromyalgia

Progen and Medigen sign collaboration agreement for muparfostat in cancer

Pierre Fabre to market bilastine in France and Belgium

Eisai plans to submit sNDA to the FDA for Dacogen in AML